-
公开(公告)号：US20230086093A1
公开(公告)日：2023-03-23
申请号：US17788717
申请日：2020-12-23
发明人： Tomoharu HOGIRI , Hiroyuki KISHIDA , Kei TAKEDOMI , Davide BRANDUARDI , Eliud OLOO , Eric FEYFANT , Osamu ICHIHARA
IPC分类号： C07K14/005 , A61P31/14 , A61K39/155
摘要： The present invention provides a mutant RSV F protein having a mutation, wherein the mutation is a substitution of a leucine corresponding to a leucine at position 141 of an amino acid sequence of SEQ ID NO: 1 or a leucine corresponding to a leucine at position 142 with a cysteine, and a substitution of a leucine corresponding to a leucine at position 373 with a cysteine, and a disulfide bond is formed between the cysteines. Further provided is a mutant RSV F protein having a mutation, wherein the mutation is a substitution of a glutamic acid corresponding to a glutamic acid at position 60 of the amino acid sequence of SEQ ID NO: 1 with a non-acidic amino acid.
-
公开(公告)号：US20230030285A1
公开(公告)日：2023-02-02
申请号：US17934234
申请日：2022-09-22
发明人： Tetsuo HAYAMA , Tomohiro TAKAHASHI , Tomoyuki OMURA , Kouji HAYASHI , Munetomo MATSUDA , Tadashi MIYAZAWA
摘要： An edaravone suspension for human oral administration includes edaravone particles, a dispersant, and water.
-
公开(公告)号：US20220298118A1
公开(公告)日：2022-09-22
申请号：US17258682
申请日：2019-07-26
IPC分类号： C07D237/14 , C07D213/89 , C07D237/08 , C07D401/04 , C07D413/04 , A61P11/00
摘要： Provided is a compound superior in an ATX inhibitory action and useful for the prophylaxis or treatment of diseases involving ATX. A carboxylic acid compound represented by the following formula (1) or a pharmacologically acceptable salt thereof: wherein each symbol is as defined in the SPECIFICATION.
-
公开(公告)号：US20220228140A1
公开(公告)日：2022-07-21
申请号：US17442798
申请日：2020-03-27
发明人： Shinji KUMAGAI , Takashi YASHIRO , Tomo ARAKI , Takayuki KANAGAWA , Chieko OKAGAKI , Hiroyuki FURUKAWA
IPC分类号： C12N15/113 , A61K31/7088 , A61P21/00
摘要： An object of the present invention is to provide a compound, a method and a pharmaceutical composition for normalizing double homeobox 4 (DUX4) of an individual in which the DUX4 gene has abnormally expressed. Provided is a modified oligonucleotide consisting of 12-30 residues. The modified oligonucleotide includes a nucleobase sequence that includes at least 8 contiguous nucleobase sequences and is complementary to an equal length portion at positions 126-147, 232-248, 1306-1325 or 1472-1495 from a 5′ end of a nucleobase of a mature mRNA of DUX4 of SEQ ID NO: 1. The nucleobase sequence of the modified oligonucleotide has at least 90% complementarity to the equal length portion in the nucleobase sequence of the mature mRNA of DUX4 of SEQ ID NO: 1.
-
公开(公告)号：US20220110915A1
公开(公告)日：2022-04-14
申请号：US17560493
申请日：2021-12-23
发明人： Tetsuo HAYAMA , Tomohiro TAKAHASHI , Tomoyuki OMURA , Kouji HAYASHI , Munetomo MATSUDA , Tadashi MIYAZAWA
摘要： An edaravone suspension for human oral administration includes edaravone particles, a dispersant, and water.
-
公开(公告)号：US11285160B2
公开(公告)日：2022-03-29
申请号：US16336667
申请日：2017-09-26
发明人： Michael P. Cooreman , Kohei Kikkawa
IPC分类号： A61K31/538 , A61K45/06
摘要： The present invention provides a pharmaceutical composition for prophylaxis and treatment of NAFLD comprising as an active ingredient a 1,4-benzoxazine compound represented by formula (I): or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, as well as a method for prophylaxis and treatment of NAFLD which comprises administering a therapeutically effective amount of the above-mentioned 1,4-benzoxazine compound represented by formula (I) and so on to a patient in need thereof.
-
公开(公告)号：US20220031609A1
公开(公告)日：2022-02-03
申请号：US17501173
申请日：2021-10-14
发明人： Tomoyuki OOMURA , Madhusudhan PUDIPEDDI , Colleen RUEGGER , Alan Edward ROYCE , Masaki SASAKI , Tokuhiro TAMURA
摘要： A solid pharmaceutical composition suitable for oral administration, comprising: (a) S 1 P receptor agonist; and (b) a sugar alcohol.
-
公开(公告)号：US20210393765A1
公开(公告)日：2021-12-23
申请号：US17431987
申请日：2020-02-19
摘要： Nucleic acids encoding rotavirus VP7 fusion proteins and rotavirus-like particle (RLPs) comprising the rotavirus VP7 fusion proteins are provided. Methods for rotavirus VP7 fusion protein and RLP production in plants are also described. The VP7 fusion protein comprises a first sequence encoding a 7-1a subdomain, a second sequence encoding a 7-2 domain and a third sequence encoding a 7-1b subdomain; wherein the sequence of the 7-2 domain is derived from a first rotavirus strain and the sequence of the 7-1a subdomain, the sequence of the 7-1b subdomain or the sequence of the 7-1a subdomain and the sequence of the 7-1b subdomain are derived from a second rotavirus strain.
-
公开(公告)号：US20210321929A1
公开(公告)日：2021-10-21
申请号：US17285160
申请日：2019-10-15
发明人： Toshihiro Hosaka , Hiroshi Sato , Makoto Tamura , Ryuta Saito
摘要： The present disclosure provides a brain wave analysis device with a computation section configured to compute a first ratio and a second ratio from a spectrum obtained by performing frequency analysis on time-series data of brain waves measured at a predetermined location of a head of a subject.
-
公开(公告)号：US20210163604A1
公开(公告)日：2021-06-03
申请号：US17042013
申请日：2019-03-27
发明人： Julia CORONELLA , Marco GYMNOPOULOS , Vincent BLOT , Ryo FUJITA , Roland NEWMAN
IPC分类号： C07K16/28 , A61K47/64 , A61P35/00 , A61K31/5517
摘要： Presented herein are novel monoclonal cMET binding agents that are conjugated to pyrrolobenzodiazepine toxins, composition thereof and uses thereof for the treatment of cancer.
-
-
-
-
-
-
-
-
-
搜索结果
419 条记录 (耗时 0.031 秒)